HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TRIA Beauty Alleges Laser Hair-Removal Center Mislead Customers, Files Suit

This article was originally published in The Rose Sheet

Executive Summary

Aesthetic device maker TRIA Beauty is bringing a lawsuit against Phoenix Rising Laser, which made "erroneous statements" about TRIA's at-home hair-removal system, according to its July 21 release

You may also be interested in...



Does Rival Hair Remover Compete With Tria Results? Tria Says no!no!

Two studies evaluating the effectiveness of competing hair-removal devices elucidate the long-term value of one system — the Tria Hair Removal Laser — while finding that Photomedex’s no!no! device offers results roughly equivalent to traditional shaving.

TRIA Preps FDA Submission For OTC Skin Rejuvenating Laser, Files For IPO

The aesthetic device maker plans to file a 510(k) this year with FDA for its OTC, non-ablative laser to treat facial wrinkles, supported in part by proceeds from an IPO worth up to $86.3 million. The hand-held device restricts a laser beam to fine “spot sizes” surrounded by untreated tissue.

TRIA Preps FDA Submission For OTC Skin Rejuvenating Laser, Files For IPO

The aesthetic device maker plans to file a 510(k) this year with FDA for its OTC, non-ablative laser to treat facial wrinkles, supported in part by proceeds from an IPO worth up to $86.3 million. The hand-held device restricts a laser beam to fine “spot sizes” surrounded by untreated tissue.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016323

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel